GlassScriptPhysician profile
Penny Chow
NPI 1336270107
$5,518.12
in general payments reported to CMS, 2019-2025
25 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,436 · 2020: $985 · 2021: $884 · 2022: $672 · 2023: $865 · 2024: $562 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $934.74 | 2021-2025 | Vraylar |
| Allergan, INC. | $638.39 | 2019-2020 | |
| Bausch Health US, LLC | $448.84 | 2020-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $434.51 | 2019-2025 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $424.23 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $412.05 | 2019-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $411.70 | 2019-2023 | Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $380.27 | 2019-2022 | |
| Axsome Therapeutics, INC. | $258.02 | 2022-2025 | Auvelity |
| Corium, LLC | $222.20 | 2022-2024 | Azstarys |
| Jazz Pharmaceuticals INC. | $188.74 | 2019-2021 | |
| Lundbeck LLC | $131.42 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $98.17 | 2020-2024 | Fanapt |
| Avanir Pharmaceuticals, INC. | $81.69 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $77.81 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $74.12 | 2019-2021 | |
| Noven Therapeutics, LLC | $61.95 | 2023-2024 | Xelstrym, Secuado |
| Indivior INC. | $57.04 | 2022-2023 | Perseris |
| Alkermes, INC. | $41.82 | 2021-2023 | Aristada, Lybalvi |
| Eisai INC. | $40.71 | 2021 | |
| Adlon Therapeutics L.P. | $32.24 | 2019-2021 | |
| Tris Pharma INC | $24.91 | 2019 | |
| Neurocrine Biosciences, INC. | $19.87 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.85 | 2019 | |
| Shire North American Group INC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Penny Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.